ArticleACS infectious diseases2019
The Proteasome as a Drug Target in the Metazoan Pathogen,
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Inhibitors of the 20S proteasome β5 subunit as potent and selective agents againstAntimicrobial agents and chemotherapy · 2025Article
- Structure-Activity Relationship and Target Investigation of Thiophen-2-yl-Pyrimidines againstbioRxiv : the preprint server for biology · 2025Article
- A genome-scale drug discovery pipeline uncovers therapeutic targets and a unique p97 allosteric binding site inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Enhancing schistosomiasis drug discovery approaches with optimized proteasome substrates.Protein science : a publication of the Protein Society · 2025Article
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site inbioRxiv : the preprint server for biology · 2025Article
- Carmaphycin B-Based Proteasome Inhibitors to Treat Human African Trypanosomiasis: Structure-Activity Relationship andACS infectious diseases · 2024Article
- Distinct substrate specificities of the three catalytic subunits of the Trichomonas vaginalis proteasome.Protein science : a publication of the Protein Society · 2024Article
- Evaluating Antimalarial Proteasome Inhibitors for Efficacy inACS omega · 2024Article
- Structural elucidation of recombinant Trichomonas vaginalis 20S proteasome bound to covalent inhibitors.Nature communications · 2024Article
- Article
- The proteasome as a drug target for treatment of parasitic diseases.Advances in parasitology · 2024Review
- Using ChEMBL to Complement Schistosome Drug Discovery.Pharmaceutics · 2023Article
- A proteasomal β5 subunit of Haemonchus contortus with a role in the growth, development and life span.Parasites & vectors · 2023Article
- Identification of Inhibitors of theACS medicinal chemistry letters · 2022Article
- Transgenesis in parasitic helminths: a brief history and prospects for the future.Parasites & vectors · 2022Review
- Microbial proteasomes as drug targets.PLoS pathogens · 2021Review
- Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis ofACS infectious diseases · 2021Article
- Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.Frontiers in immunology · 2021Review
- Large-scale RNAi screening uncovers therapeutic targets in the parasiteScience (New York, N.Y.) · 2020Article
- Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?International journal for parasitology. Drugs and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Betsaida Bibo-VerdugoCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Steven C WangCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Jehad AlmalitiScripps Institution of Oceanography , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Anh P TaSkaggs School of Pharmacy and Pharmaceutical Sciences , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Zhenze JiangSkaggs School of Pharmacy and Pharmaceutical Sciences , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Derek A WongSkaggs School of Pharmacy and Pharmaceutical Sciences , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Christopher B LietzSkaggs School of Pharmacy and Pharmaceutical Sciences , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Brian M SuzukiCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Nelly El-SakkaryCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Vivian HookSkaggs School of Pharmacy and Pharmaceutical Sciences , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.ORCID 0000-0001-6461-7024
Guy S SalvesenSanford Burnham Prebys Medical Discovery Institute , 10901 North Torrey Pines Road , La Jolla , California 92037 , United States.
William H GerwickCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.ORCID 0000-0003-1403-4458
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.
Anthony J O'DonoghueCenter for Discovery and Innovation in Parasitic Diseases , University of California, San Diego , 9500 Gilman Drive , La Jolla , California 92093 , United States.ORCID 0000-0001-5695-0409
University of California San Diego · USSanford Burnham Prebys Medical Discovery Institute · USScripps Institution of Oceanography · USUniversity of Jordan · JO
Funding
FELLOWSHIP IN GERIATRIC MENTAL HEALTHT32MH019934 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elizabeth W Twamley · 1994 to 2026
$9.5MSurvival Mechanisms for Apoptotic CaspaseR01GM099040 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SALVESEN, GUY S. · 2012 to 2020
$3.8MExploring the proteasome as a new drug target to treat schistosomiasisR21AI133393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI O'DONOGHUE, ANTHONY JOHN · 2017 to 2018
$426kDefining the death transcriptome of Schistosoma mansoni to construct a molecular drug screenR21AI126296 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR · 2017 to 2018
$415kNIAID NIH HHS HHSN272201300014INIAID NIH HHS HHSN272201700014CNIAID NIH HHS R21 AI126296NIAID NIH HHS R21 AI133393NIGMS NIH HHS R01 GM099040NIMH NIH HHS T32 MH019934
Abstract
Proteases are fundamental to successful parasitism, including that of the schistosome flatworm parasite, which causes the disease schistosomiasis in 200 million people worldwide. The proteasome is receiving attention as a potential drug target for treatment of a variety of infectious parasitic diseases, but it has been understudied in the schistosome. Adult
Indexed as
AnimalsAntineoplastic AgentsBortezomibCaspasesCysteine Proteinase InhibitorsDrug Delivery SystemsHep G2 CellsHumansLeupeptinsOligopeptidesProteasome Endopeptidase ComplexProteasome InhibitorsSchistosoma mansoniAntineoplastic Agentsbenzyloxycarbonylleucyl-leucyl-leucine aldehydeBortezomibcarfilzomibcarmaphycin BCaspasesCysteine Proteinase InhibitorsLeupeptinsOligopeptidesProteasome Endopeptidase ComplexProteasome InhibitorsbortezomibcarfilzomibcarmaphycinMG132proteasomeSchistosomaschistosomiasis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.